Patient Characteristics of CMV-Seropositive Patients Undergoing Autologous PBSC Transplantation
| . | CD34-Selected . | Unselected . |
|---|---|---|
| No. of patients | 31 | 237 |
| Median age (range) | 52 (5-62) | 48 (2-69) |
| Gender (M/F) | 15/16 | 76/161 |
| Diagnosis | ||
| MM | 6 (19.4%) | 26 (11.0%) |
| NHL | 10 (32.3%) | 38 (16.0%) |
| HD | 1 (3.2%) | 12 (5.1%) |
| ALL | 2 (6.5%) | — |
| Breast cancer | 4 (12.9%) | 108 (45.6%) |
| CLL | 4 (12.9%) | — |
| Neuroblastoma | 1 (3.2%) | 11 (4.7%) |
| Systemic sclerosis | 3 (9.7%) | — |
| Ovarian cancer | — | 14 (5.9%) |
| Germ cell | — | 2 (0.8%) |
| AML | — | 9 (3.7%) |
| CML | — | 5 (2.1%) |
| Brain cancer | — | 1 (0.4%) |
| Sarcoma | — | 7 (3.0%) |
| Carcinoma | — | 4 (1.7%) |
| Prior chemotherapy | ||
| Median no. of regimens (range) | 2 (1-4) | 2 (1-6) |
| Prior XRT | 6 (19.4%) | 68 (28.7%) |
| High-dose regimen | ||
| TBI-based | 14 (45.2%) | 34 (14.3%) |
| Non–TBI-based | 17 (54.8%) | 203 (85.7%) |
| No. of CD34 (×106 cells/kg) infused: | ||
| Median (range) | 4.83 (2.34-14.64) | 6.97 (2.54-65.5) |
| Posttransplant steroids | 11 (35.4%) | 74 (31.2%) |
| . | CD34-Selected . | Unselected . |
|---|---|---|
| No. of patients | 31 | 237 |
| Median age (range) | 52 (5-62) | 48 (2-69) |
| Gender (M/F) | 15/16 | 76/161 |
| Diagnosis | ||
| MM | 6 (19.4%) | 26 (11.0%) |
| NHL | 10 (32.3%) | 38 (16.0%) |
| HD | 1 (3.2%) | 12 (5.1%) |
| ALL | 2 (6.5%) | — |
| Breast cancer | 4 (12.9%) | 108 (45.6%) |
| CLL | 4 (12.9%) | — |
| Neuroblastoma | 1 (3.2%) | 11 (4.7%) |
| Systemic sclerosis | 3 (9.7%) | — |
| Ovarian cancer | — | 14 (5.9%) |
| Germ cell | — | 2 (0.8%) |
| AML | — | 9 (3.7%) |
| CML | — | 5 (2.1%) |
| Brain cancer | — | 1 (0.4%) |
| Sarcoma | — | 7 (3.0%) |
| Carcinoma | — | 4 (1.7%) |
| Prior chemotherapy | ||
| Median no. of regimens (range) | 2 (1-4) | 2 (1-6) |
| Prior XRT | 6 (19.4%) | 68 (28.7%) |
| High-dose regimen | ||
| TBI-based | 14 (45.2%) | 34 (14.3%) |
| Non–TBI-based | 17 (54.8%) | 203 (85.7%) |
| No. of CD34 (×106 cells/kg) infused: | ||
| Median (range) | 4.83 (2.34-14.64) | 6.97 (2.54-65.5) |
| Posttransplant steroids | 11 (35.4%) | 74 (31.2%) |